Clinical trial NCT05255107: Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
Official title: Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Keratitis
Corneal Ulcer
Lead sponsor: Peschke GmbH
Sponsor class: INDUSTRY
First posted: 2022-02-24
Enrollment: 468
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Simple block randomization will be used to assign subjects in a 1:1 ratio to 2 treatment arms. Subjects will be randomized consecutively (not stratified by site) to ensure balance between the treatment arms at any point in the study.
Primary purpose: TREATMENT

Brief summary: This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Riboflavin 0.23% PESCHKE-L Solution) administered in conjunction with the UV-A light as a photosensitizer. The PXL Platinum 330 System is intended to induce corneal collagen CXL to improve the biomechanical properties of the cornea by strengthening the corneal tissue in the anterior stroma. Corneal collagen CXL is performed by pretreating the cornea with riboflavin ophthalmic solution beginning 40 min before UV-A light exposure to saturate the corneal tissue with the riboflavin photosensitizer. The cornea is then irradiated with UV-A light (365 nm) at an irradiance of 18 mW/cm2 (5 seconds on, 5 seconds off) for 10 min. Exposure of the cornea to this UV-A light regimen after topical administration of riboflavin ophthalmic solution has been shown to induce CXL of the corneal collagen fibrils, with a resultant increase in tensile strength and diameter of the collagen fibrils. Clinically, CXL has been shown to stabilize the corneal curvature in eyes with progressive keratoconus, with no significant change in the refractive index of the cornea. Numerous reports and a few clinical trials have also shown benefit in aiding resolution of infective corneal ulcers.

Detailed description: This is a prospective, 2-arm parallel-group, single-masked, randomized multicenter study to determine the safety and effectiveness of the PXL Platinum 330 System for performing CXL in eyes with previously untreated corneal ulcers. Subjects with documented infectious corneal ulcers that have not been treated (treatment na ve) will be evaluated initially for suitability as candidates for CXL. Subjects who are candidates for CXL will be asked to participate in this study and will undergo the required screening procedures to determine study eligibility. Informed consent will be obtained from each subject before performance of any required study procedures that are not part of the investigator's routine examination. After completing screening procedures, the diagnosis for each eligible eye will be confirmed. Subjects will be randomized to 1 of 2 groups, both including standard of care (SOC) treatment:

1. SOC: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion
2. CXL + SOC: Moxifloxacin 0.5% eyedrop therapy + CXL

Eyes undergoing CXL will have topical anesthetic administered and then have topical riboflavin instilled onto the cornea every 2 min (or longer as needed to assure adequate corneal penetration), after which the cornea will be exposed to UV-A pulsed light 18 mW/cm2 for 10 min. Riboflavin instillation will continue every 2 min during CXL. The CXL procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UV-A light source and riboflavin solution). All use of the PXL Platinum 330 System will be in accordance with this protocol and the general instructions provided by the manufacturer (PESCHKE) in the PXL Platinum 330 Illumination System Operator's Manual. All subjects will be evaluated at Screening/Baseline, Day 0 (Randomization/Treatment), Day 1, Day 3 ( 1 day), Week 1 ( 2 days), Week 2 ( 2 days), and Week 4 ( 3 days) after treatment. Efficacy monitoring throughout the study will include observations at appropriate times for re-epithelialization, size of infection, and corneal culture results. Safety monitoring throughout the study will include observations at appropriate times for pain, IOP, BSCVA, corneal scar size, AEs, clinically significant findings on ophthalmic examination, dilated fundus examination, and slit lamp examination. After treatment, subjects will be followed at the treating physician's discretion.

Eligibility criteria: Inclusion Criteria:

* Subjects who have one or both eyes that meet the following criteria will be considered candidates for this study:

  1. 18 years of age or older
  2. Ulcers that have not been treated with ophthalmic antibiotic eyedrops (eg, quinolone, polymyxin/trimethoprim, erythromycin, vancomycin, tobramycin, cefazolin, or other ophthalmic antimicrobials) in the preceding 30 days erythromycin, vancomycin, tobramycin, cefazolin, or other ophthalmic antimicrobials) in the preceding 30 days
  3. Consent to a corneal culture for suspected bacterial keratitis (defined as a corneal epithelial defect of any size with an infiltration of the underlying stroma)
  4. Signed written informed consent
  5. Willingness and ability to comply with schedule for follow-up visits
  6. Minimum corneal thickness \>300 μm

Exclusion Criteria:

* All subjects meeting any of the following criteria will be excluded from this study:

  1. Presence of a perforated corneal ulcer
  2. Presence of a corneal ulcer that had produced a descemetocele
  3. Presence of a corneal ulcer deeper than 50% depth or 275 μm in the cornea
  4. Any active ocular infection other than the corneal ulcer to be treated
  5. Suspicion of amoebic or viral keratitis requiring treatment with topical anti-amoebic or topical antiviral ophthalmic medications
  6. Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye(s) for future complications. This may include history of or active corneal disease (eg, herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, acanthamoeba, etc.)
  7. Uncontrolled systemic disease, especially a collagen-vascular or rheumatologic condition that could be contributing to the corneal condition
  8. Pregnancy (or plan to become pregnant) or lactation during the course of the study
  9. A known sensitivity to study medications
  10. Presence of nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests

Primary outcomes:
measure: To evaluate the safety and effectiveness of corneal collagen CXL for treating previously untreated corneal ulcers
timeFrame: Week 2 (#+/- 2 study days).
Secondary outcomes:
Other outcomes:
Locations:
city: Littleton
country: United States
facility: Colorado Eye Consultants
state: Colorado
city: Fort Myers
country: United States
facility: Gorovoy M.D Eye Specialists
state: Florida
city: Tampa
country: United States
facility: Bay Area Eye Institute
state: Florida
city: Indianapolis
country: United States
facility: Price Vision Group
state: Indiana
city: Teaneck
country: United States
facility: The cornea & Laser Eye Institute-NJ
state: New Jersey
city: Babylon
country: United States
facility: SightMD
state: New York
city: Columbia
country: United States
facility: Prisma Health Opthalmology
state: South Carolina
city: Chattanooga
country: United States
facility: Woolfson Eye
state: Tennessee
city: Houston
country: United States
facility: Houston Eye Associates
state: Texas
city: Lackland Air Force Base
country: United States
facility: San Antonio Eye Center
state: Texas
city: Milwaukee
country: United States
facility: Milwaukee Eye Surgeons
state: Wisconsin
city: Oshkosh
country: United States
facility: Valley Eye
state: Wisconsin
Study officials:
affiliation: Peschke GmbH
name: Yvette Viscuso
role: STUDY_DIRECTOR
affiliation: Pacific Clear Vision Institute
name: Bala Ambati
role: PRINCIPAL_INVESTIGATOR
References: